Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Scores Stratify Risk of Developing Type 1 Diabetes

By LabMedica International staff writers
Posted on 15 May 2018
Approximately 0.3% of newborns will develop autoimmunity to pancreatic beta cells in childhood and subsequently develop type 1 diabetes before adulthood. More...
Primary prevention of type 1 diabetes will require early intervention in genetically at-risk infants.

Precision medicine typically relies on the ability to identify individuals with precise genetic elements that define a disease. These elements may be used not only to select optimal treatment modalities, but also to identify individuals who may benefit from preventative interventions.

An international team of scientists led by those at the Technische Universität Dresden (Dresden, Germany) performed a case-control study and followed genetically at-risk children at 3- to 6-monthly intervals from birth for the development of islet autoantibodies and type 1 diabetes. Infants were enrolled between September 1, 2004 and February 28, 2010 and monitored until May 31, 2016. A total of 421,047 newborn children were screened for high-risk Human leukocyte antigen (HLA) genotypes for type 1 diabetes.

The risk (positive predictive value) for developing multiple islet autoantibodies (pre-symptomatic type 1 diabetes) and type 1 diabetes was determined in 4,543 children who had no first-degree relatives with type 1 diabetes and either a heterozygous HLA DR3 and DR4-DQ8 risk genotype or a homozygous DR4-DQ8 genotype, and in 3,498 of these children in whom genetic scores were calculated from 41 single nucleotide polymorphisms.

The scientists found that in the children with the HLA risk genotypes, risk for developing multiple islet autoantibodies was 5.8% by age six years, and risk for diabetes by age 10 years was 3.7%. Risk for developing multiple islet autoantibodies was 11.0% in children with a merged genetic score of >14.4 (n = 907) compared to 4.1% in children with a genetic score of equal to or less than 14.4 (n = 2,591). Risk for developing diabetes by age 10 years was 7.6% in children with a merged score of >14.4 compared with 2.7% in children with a score of ≤14.4. In children with a merged score of >14.4, risk for multiple islet autoantibodies was similar and consistently >10% in Europe and in the USA and the risk was greater in males than in females.

The authors concluded that a type 1 diabetes genetic score identified infants without family history of type 1 diabetes who had a greater than 10% risk for pre-symptomatic type 1 diabetes, and a nearly two-fold higher risk than children identified by high-risk HLA genotypes alone. This finding extends the possibilities for enrolling children into type 1 diabetes primary prevention trials. The study was published on April 3, 2018, in the journal PLoS Medicine.

Related Links:
Technische Universität Dresden


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.